Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04844086
Other study ID # Eden 2020-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date March 2, 2021
Est. completion date May 12, 2022

Study information

Verified date May 2022
Source Eden BioCell Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients. Approximately 24 subjects will be enrolled and it is anticipated approximately 16 subjects will be infused at the varied doses of T cells.


Description:

This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients. Approximately 24 subjects will be enrolled and it is anticipated approximately 16 subjects will be infused at the varied doses of T cells. This study will very rapidly administer T cells that are genetically modified by electroporation using DNA plasmids from the SB system to co-express CD19RCD8CD28 (the CAR), mbIL15, and HER1t. The presence of mbIL15 may allow for reduced doses of CAR-T cells to be infused to reduce the risk for adverse events, such as cytokine release syndrome (CRS). The key features of study design are listed below. 1. Uncontrolled 2. Blinding: open-label 3. Randomized: no 4. Duration of treatment: single infusion within day 5. Titration: none 6. Single center, Taiwan


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date May 12, 2022
Est. primary completion date May 12, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria for Enrollment: A subject may participate in the study if all the following criteria is met: - Patients with CD19+ malignancies that are refractory to or relapsed after current standard treatment (including allogeneic or autologous HSCT) and not suitable for other treatment options, such as second-time HSCT. CD19+ malignancies include: 1. Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL): 1. Refractory ALL is defined as failure to achieve CR at the end of induction. 2. Relapsed ALL is defined as reappearance of blasts in the blood or bone marrow (= 5%) or in any extramedullary site after a CR. 2. Relapsed/Refractory B-cell originated Non-Hodgkin Lymphoma (NHL) including 1) de-novo diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, 2) large-B cell lymphoma transformed from indolent lymphomas, 3) follicular lymphoma of all grades, 4) mantle cell lymphoma, and 5) CD20(+) high-grade B-cell lymphomas. Refractory disease for lymphoma is defined as: 1. Progressive disease or stable disease lasting < 6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence < 12 months after prior autologous HSCT. 2. Prior therapy must have included an anti-CD20 monoclonal antibody-containing regimen and an anthracycline-containing chemotherapy regimen 3. For patients with transformed follicular lymphoma (TFL), prior chemotherapy for follicular lymphoma and subsequent refractory disease after transformation to DLBCL. 4. At least one measurable lesion, demonstrating that the nodal lesion is = 1.5 cm in the longest diameter or the extranodal lesion is = 1.0 cm in the longest diameter, according to the Lugano Classification (2014). - Patients must have received at least 2 prior lines of therapy. HSCT (allogeneic or autologous) can be accounted as one of the prior line therapy, and the subjects must have been at least 3 months from prior HSCT. - Karnofsky Performance Scale = 60 - Patient able to provide written informed consent for participating in the study - Age = 20 years and = 75 years old at the time of providing informed consent - Patients shall be at least 3 weeks from the last cytotoxic chemotherapy before apheresis. Short-acting targeted therapies (e.g., tyrosine kinase inhibitors) must be stopped > 72 hours before apheresis. - Monoclonal antibody use including Anti-CD20 therapy has been discontinued at least 4 weeks before leukapheresis and CAR-T cells infusion except for systemic inhibitory/stimulatory immune checkpoint therapy. Immune checkpoint therapy has been discontinued at least 3 half-lives before leukapheresis (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists, etc.). - Absolute lymphocyte count (ALC) = 1.0x109/L and absolute number of CD3+ T cells (ATC) = 0.3x109/L, absolute neutrophil count (ANC) = 1.0 x109/L for lymphoma and ANC = 0.5 x109/L for ALL, platelets = 50.0 x109/L, hemoglobin = 80.0 g/L within 7 days before apheresis. - Adequate organ function demonstrated by the following: 1. Renal: serum creatinine <2 x upper limit of normal (ULN) 2. Hepatic: ALT/AST = 2.5 x ULN or = 5 x ULN if documented liver metastases, total bilirubin = 1.5 mg/dL, except in subjects with Gilbert's Syndrome in whom total bilirubin must be = 3.0 mg/dL. 3. Cardiac: no clinically significant ECG findings, hemodynamically stable and LVEF = 45% confirmed by echocardiogram 4. Pulmonary: baseline oxygen saturation > 90% on room air - 10. Not receiving anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell immunosuppressive antibodies, donor-lymphocyte infusion or T-cell infusion for the past 3 weeks before apheresis; - Negative serology for Anti-HTLV-I / HTLV-II (DHTLV I/II) Exclusion Criteria for Enrollment A subject who met any of the following criteria is not eligible to enter the study: - Received previous treatment with anti-CD19 therapy; - Is with a history of CNS malignancy and/or active CNS diseases; - Has previous or concurrent malignancies other than CD19+ malignancies; - Has active neurological, autoimmune, or inflammatory disorders; - Has clinically significant cardiac diseases, or cardiac arrhythmia not controlled with medical treatment; - Has cardiac involvement with lymphoma; - Has any active infections, conditions, and diseases that may interfere with the assessment of safety and efficacy of the study deemed by the investigator or designee; - Received live vaccine within 6 weeks of the screening - Received radiation therapy within 2 weeks of the planned CAR-T cells infusion; - Is with positive serology for HIV; - Is with positive hepatitis B or hepatitis C infection, defined as positive HBs Ag or positive Anti-HCV Ab; - Active graft versus host disease (GVHD) = grade 2 using the CIBMTR Acute GVHD Grading System or requiring systemic steroid therapy greater than physiologic dosing; Note: Overall grading of GVHD is based on the criteria published by Przepiorka et al., Bone Marrow Transplant 1995; 15(6):825-8, see the GVHD Grading and Staging table at CIBMTR Forms Instruction Manual (Last updated: 2020/03/10), page 301-303 (Available at https://www.cibmtr.org/manuals/fim, accessed on 08 Apr 2020). - Use of investigational medicinal product within 30 days before the screening; - Positive beta HCG in female of child-bearing potential (defined as not post-menopausal for 12 months) or history of previous surgical sterilization or lactating females. - Patients with known allergy to mouse products or cetuximab. Inclusion Criteria for Lymphodepletion and T-Cell Infusion: - Prior to Lymphodepletion (LD): 1. Patients must have no evidence of clinically significant infection; 2. No acute neurological toxicity >grade 1 (with the exception of peripheral sensory neuropathy) prior to conditioning chemotherapy; 3. No clinically significant cardiac dysfunction; 4. Serum creatinine < 2x ULN; 5. No evidence of grade =2 acute GVHD; 6. Pulmonary: oxygen saturation > 90% on room air; 7. Adequacy of T cells apheresis products to manufacture CAR-T product. - Prior to CAR-T cells infusion: 1. Patients shall be at least 4 weeks from the last cytotoxic chemotherapy (excluding the study mandated lymphodepleting chemotherapy) before infusion. Short-acting targeted therapies (e.g., tyrosine kinase inhibitors) must be stopped > 72 hours before infusion. 2. At least 4 weeks from anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell immunosuppressive antibodies, donor-lymphocyte infusion or T-cell infusion; 3. Steroids, if given as GVHD therapy, must be stopped >72 hours prior to infusion. However, the following physiological replacement doses of steroids are allowed: < 6-12 mg/m2/day hydrocortisone or equivalent. 4. Non-hematologic toxicity grade =2 (CTCAE version 5) related to the lymphodepleting chemotherapy until the toxicity has resolved to grade =1 and the subject is afebrile; 5. No grade >2 neurologic, pulmonary, cardiac, gastrointestinal, renal, or hepatic (excluding albumin) toxicity; 6. Adequacy of the CAR-T cells for infusion. Exclusion Criteria For Lymphodepletion and T-Cell Infusion: A subject who meets any of the following criteria should not undergo LD or infusion of CAR-T cells. - New onset of cardiac arrhythmia not uncontrolled with medications; - Hypotension warrants the use of vasopressor; - Active infections within 1 week prior to CAR-T infusion that necessitate the use of oral or intravenous anti-infective treatments; subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible as long as there is no evidence of active infection. - Presence of CNS or neurological abnormalities; - Received HSCT after screening or planned to receive HSCT during the study period; - Any conditions not suitable for the CAR-T cells infusion in the PI or designee's judgement.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
RPM CD19-mbIL15-CAR-T cells
Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard "3+3" design will be applied. Drug: Fludarabine Fludarabine is used for lymphodepletion. Drug: Cyclophosphamide Cyclophosphamide is used for lymphodepletion

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
Eden BioCell Ltd. National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximun Tolerated Dose (MTD) of the RPM CD19- mbIL15-CAR-T MTD is the highest dose at which no more than 1 of 6 patients experiences a dose limiting toxicity. within 4 weeks after infusion
Secondary Feasibility of the product manufacturing process Percentage of subjects for whom the desired dose of RPM CD19 mbIL15 CAR-T cells can be successfully manufactured. day 0 to month 12
Secondary Adverse events related to treatment The incidence and severity of AE of Cytokine Release Syndrome and neurotoxicity. day 0 to month 12
Secondary Persistence of infused T cells Duration of CAR-T cell persistence by vector copy number (VCN). day 0 to month 12
Secondary Safety Switch Function Measure the decrease of RPM CD19 mbIL15-CAR-T cells after cetuximab administration. day 0 to month 12
Secondary Immunogenicity Immnuogenicity (humoral) defined as the percent of subjects that develop anti-drug antibodies. day 0 to month 12
Secondary Cytokine Profile levels of cytokine in serum, including IL-6, IL-10, IFN-?, TNFa concentration (pg/mL), measured by Elisa. day 0 to month 12
Secondary Homing ability of the infused T-cells Percent of subjects with measurable RPM CD19 mbIL15 CAR-T cells in bone marrow. day 0 to month 12
Secondary Disease response after T cell infusion Objective response rate (ORR), complete response (CR), Complete response with incomplete blood count recovery (CRi), partial response (PR) day 0 to month 12
Secondary Progression-Free Survival Measured from infusion of RPM CD19 mbIL15 CAR-T cells until the documentation of disease progression or death due to any cause, whichever occurs first. day 0 to month 12
Secondary Overall Survival Overall survival will be determined as time fro the start of RPM CD19-mbIL15-CAR-T cells infusion until death due to any cause. day 0 to month 12
Secondary Emergence of CD19neg malignant B cells CD19 expression of tumor tissue when tumor relapse and progress. day 0 to month 12
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1